Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New targeted drug shows promise for Hard-to-Treat cancers

NCT ID NCT03093116

Disease control Sponsor: Turning Point Therapeutics, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called repotrectinib in people with advanced solid tumors that have certain gene changes (ALK, ROS1, or NTRK). The trial has two parts: first, finding a safe dose, and second, seeing how well the drug shrinks tumors. About 500 adults with advanced cancers that have not responded to other treatments are being enrolled.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
repotrectinib (TPX-0005) capsules
What this could lead to
If successful, this could lead to a new targeted treatment option for people with advanced solid tumors that have specific genetic changes (ALK, ROS1, or NTRK).
What could go wrong
This is an early phase 1/2 trial, so safety and effectiveness are not yet proven. It may not work for all participants, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2017

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

PHASE 1 Key Inclusion Criteria: 1. Histologically or cytologically confirmed diagnosis of locally advanced, or metastatic solid tumor (including primary CNS tumors) (Stage IV, American Joint Committee on Cancer v.7) that harbors an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement by protocol specified tests. 2. ECOG PS 0-1. 3. Age ≥18 (or age ≥ 20 of age as required by local regulation). 4. Capability to swallow capsules intact (without chewing, crushing, or opening). 5. At least 1 measurable target lesion according to RECIST version 1.1. CNS-only measurable disease as defined by RECIST version 1.1 is allowed. 6. Prior cytotoxic chemotherapy is allowed. 7. Prior immunotherapy is allowed. 8. Resolution of all acute toxic effects (excluding alopecia) of any prior anti-cancer therapy to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03 Grade less than or equal to 1. 9. Patients with asymptomatic CNS metastases (treated or untreated) and/or asymptomatic leptomeningeal carcinomatosis are eligible to enroll if they satisfy the protocol specified criteria. 10. Baseline laboratory values fulfilling the following requirements:Absolute neutrophils count (ANC) ≥1500/mm3 (1.5 × 109/L); Platelets (PLTs) ≥100,000/mm3 (100 × 109/L); Hemoglobin ≥ 9.0 g/dL transfusions are allowed; Serum creatinine or creatinine clearance Within normal limits or \> 40 mL/min; Total serum bilirubin \< 1.5 × ULN; Liver transaminases (ASTs/ALTs) \< 2.5 × ULN; \< 5 × ULN if liver metastases are present Alkaline phosphatase (ALP); \< 2.5 × ULN; \< 5 × ULN if liver and/or bone metastasis are present; Serum calcium, magnesium, and potassium Normal or CTCAE grade ≤ 1 with or without supplementation 11. Life expectancy ≥ 3 months. PHASE 2 Key Inclusion Criteria 1. Histologically or cytologically confirmed diagnosis of locally advanced, or metastatic solid tumor (including primary CNS tumors) that harbors a ROS1, or NTRK1-3 gene fusion. 2. Subject must have a documented ROS1 or NTRK1-3 gene fusion determined by tissue-based local testing using either: 1. a next-generation sequencing (NGS) or quantitative polymerase chain reaction (qPCR) test will be accepted to determine molecular eligibility. • Adequate tumor tissue needs to be sent to the Sponsor designated central diagnostic laboratory for retrospective confirmation by a central diagnostic laboratory test selected by the Sponsor. OR 2. a fluorescence in situ hybridization (FISH) test AND prospective confirmation of fusion status by a central diagnostic laboratory test selected by the Sponsor PRIOR to enrollment will be accepted to determine molecular eligibility. * Adequate tumor tissue must be sent to the Sponsor designated central diagnostic laboratory for prospective confirmation by a central diagnostic laboratory test selected by the Sponsor PRIOR to enrollment. 3. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1. 4. Age ≥12 (or age ≥ 20 as required by local regulation). 5. Willing and able to provide written institutional review board (IRB)/institutional ethics committee-approved Informed Consent or an Assent signed by a parent or legal guardian for subjects age 12 to 17. 6. At least 1 measurable target lesion according to RECIST (v1.1) prospectively confirmed by Blinded Independent Central Radiology Review (BICR), selected by Sponsor, PRIOR to enrollment. Subjects with CNS-only measurable disease ≥10 mm as defined by RECIST (v1.1) are eligible. 7. Subjects with advanced solid tumors harboring ROS1, NTRK1, NTRK2, or NTRK3 rearrangement will be assigned into 6 distinct expansion (EXP) cohorts provided all inclusion and exclusion criteria are met. i. EXP-1: ROS1 TKI-naïve ROS1+ NSCLC ii. EXP-2: 1 Prior ROS1 TKI and 1 Platinum based chemo ROS1+ NSCLC iii. EXP-3: 2 Prior ROS1 TKIs ROS1+ NSCLC (No Chemo or IO) iv. EXP-4: 1 Prior ROS1 TKI ROS1+ NSCLC (No Chemo or IO) v. EXP-5: TRK TKI-naïve NTRK+ solid tumors vi. EXP-6: TRK TKI-pretreated NTRK+ solid tumors 8. Subjects with asymptomatic CNS metastases (treated or untreated) and/or asymptomatic leptomeningeal carcinomatosis are eligible to enroll if they satisfy the protocol specified criteria. 9. Baseline laboratory values fulfilling the following requirements:Absolute neutrophils count (ANC) ≥1500/mm3 (1.5 × 109/L); Platelets (PLTs) ≥100,000/mm3 (100 × 109/L); Hemoglobin ≥ 9.0 g/dL transfusions are allowed; Serum creatinine or creatinine clearance \> 40 mL/min; Total serum bilirubin \< 1.5 × ULN; Liver transaminases (ASTs/ALTs) \< 2.5 × ULN; \< 5 × ULN if liver metastases are present Alkaline phosphatase (ALP); \< 2.5 × ULN; \< 5 × ULN if liver and/or bone metastasis are present; Serum calcium, magnesium, and potassium Normal or CTCAE grade ≤ 1 with or without supplementation 10. Life expectancy ≥ 3 months. Key Exclusion Criteria PHASE 1 and PHASE 2 1. Concurrent participation in another therapeutic clinical trial. 2. Symptomatic brain metastases or leptomeningeal involvement. 3. History of previous cancer, except for squamous cell or basal-cell carcinoma of the skin, or any in situ carcinoma that has been completely resected, requiring therapy within the previous 2 years. 4. Major surgery within 4 weeks of start of repotrectinib treatment. Radiation therapy (except palliative to relieve bone pain) within 2 weeks of study entry. Palliative radiation (≤10 fractions) must have been completed at least 48 hours prior to study entry 5. Clinically significant cardiovascular disease (either active or within 6 months prior to enrollment): myocardial infarction, unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure (New York Heart Association Classification Class ≥ II), cerebrovascular accident or transient ischemic attack, symptomatic bradycardia, requirement for anti-arrhythmic medication. Ongoing cardiac dysrhythmias of NCI CTCAE grade ≥2 6. Any of the following cardiac criteria: Mean resting corrected QT interval (ECG interval measured from the onset of the QRS complex to the end of the T wave) for heart rate (QTcF) \> 470 msec obtained from 3 ECGs, using the screening clinic ECG machine-derived QTc value Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block, second degree heart block, PR interval \> 250 msec) Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or any concomitant medication known to prolong the QT interval. 7. Known active infections (bacterial, fungal, viral including HIV positivity). 8. Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would impact drug absorption. 9. Peripheral neuropathy of CTCAE ≥grade 2. 10. History of extensive, disseminated, bilateral, or presence of CTCAE grade 3 or 4 interstitial fibrosis or interstitial lung disease including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis, and pulmonary fibrosis. Subjects with history of prior radiation pneumonitis are not excluded.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced solid tumor with NTRK1 rearrangement are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

adenocarcinoma bronchial neoplasm bronchogenic carcinoma carcinoma colonic disorder colonic neoplasm digestive system disorder digestive system neoplasm Digestive System Neoplasms endocrine system disorder Head and Neck Neoplasms intestinal cancer intestinal disorder lung disorder lung neoplasm malignant endocrine neoplasm metastatic malignant neoplasm neoplasm Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Germ Cell and Embryonal neuroendocrine carcinoma neuroendocrine neoplasm non-small cell lung carcinoma NTRK fusion positive cancer primitive neuroectodermal tumor respiratory system disorder respiratory tract neoplasm sarcoma Thoracic Neoplasms thyroid gland disorder Thyroid Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Locally advanced solid tumors Metastatic solid tumors

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    65 sites in 10 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Anhui Provincial Hospital

    RECRUITING

    Hefei, 230001, China

  • Asan Medical Center

    RECRUITING

    Seoul, 05505, South Korea

  • Baptist Memorial Hospital Baptist Cancer Center

    RECRUITING

    Memphis, Tennessee, 38120, United States

  • Beijing Cancer hospital

    RECRUITING

    Beijing, Beijing Municipality, 100142, China

  • Centre Antoine-Lacassagne

    RECRUITING

    Nice, 06189, France

  • Centre Georges-Francois Leclerc

    RECRUITING

    Dijon, 21079, France

  • Centre Hospitalier Universitarie Grenoble Alpes (Chuga)

    RECRUITING

    Grenoble, 38043, France

  • Centro di Riferimento Oncologico

    RECRUITING

    Pordenone, 33081, Italy

  • Chonnam National University Hwasun Hospital

    RECRUITING

    Hwasun-eup, Hwasun-gun, Jeollanam-do, 519-763, South Korea

  • Chris O'Brien LifeHouse

    RECRUITING

    Camperdown, New South Wales, 2050, Australia

  • Daping Hospital, the Third Affiliated Hospital of Third Military Medical University /Cancer Center

    RECRUITING

    Daping, Chongqing Municipality, 00000, China

  • Ehime University Hospital

    RECRUITING

    Tōon, Ehime, 791-0295, Japan

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    RECRUITING

    Milan, MI, 20133, Italy

  • Guangdong Provincial People'S Hospital

    RECRUITING

    Guangzhou, Guangdong, 510120, China

  • Henan Cancer Hospital/The 1st pneumology department

    RECRUITING

    Zhengzhou, 00000, China

  • Hokkaido University Hospital

    RECRUITING

    Sapporo, Hokkaido, 0608648, Japan

  • Hospital Universitario HM Sanchinarro CIOCC

    RECRUITING

    Madrid, 28050, Spain

  • Hospital Unversitario Val D'Hebrón

    RECRUITING

    Barcelona, 8035, Spain

  • Hunan Cancer Hospital-thoracic oncology II

    RECRUITING

    Changsha, Hunan, 410013, China

  • IRCCS Istituto Regina Elena Oncologia Medica 2

    RECRUITING

    Roma, 144, Italy

  • Institute Gustave Roussy

    RECRUITING

    Villejuif, 98405, France

  • Jilin Cancer Hospital/Medical Oncology Department

    RECRUITING

    Changchun, Jilin, 130012, China

  • Jilin Cancer Hospital/Medical Oncology Department

    RECRUITING

    Changchun, Jilin, 130012, China

  • Kanagawa cancer center

    RECRUITING

    Yokohama, Kanagawa, 2418515, Japan

  • Liaoning Cancer Hospital

    RECRUITING

    Shenyang, Liaoning, 110801, China

  • Local Institution - 1001

    COMPLETED

    Orange, California, 92868, United States

  • Local Institution - 1002

    ACTIVE_NOT_RECRUITING

    New York, New York, 10065, United States

  • Local Institution - 1003

    COMPLETED

    Aurora, Colorado, 80045, United States

  • Local Institution - 1004

    COMPLETED

    Boston, Massachusetts, 02214, United States

  • Local Institution - 2101

    COMPLETED

    Orange, California, 92868, United States

  • Local Institution - 2102

    COMPLETED

    New York, New York, 10065, United States

  • Local Institution - 2103

    COMPLETED

    Aurora, Colorado, 80045, United States

  • Local Institution - 2105

    COMPLETED

    Ann Arbor, Michigan, 48109, United States

  • Local Institution - 2106

    COMPLETED

    Washington D.C., District of Columbia, 20007, United States

  • Local Institution - 2107

    COMPLETED

    Seattle, Washington, 98109, United States

  • Local Institution - 2108

    COMPLETED

    Philadelphia, Pennsylvania, 19111-2497, United States

  • Local Institution - 2109

    COMPLETED

    Cleveland, Ohio, 44195, United States

  • Local Institution - 2110

    COMPLETED

    Washington D.C., District of Columbia, 20016, United States

  • Local Institution - 2111

    COMPLETED

    Detroit, Michigan, 48201, United States

  • Local Institution - 2112

    COMPLETED

    Canton, Ohio, 44718, United States

  • Local Institution - 2113

    COMPLETED

    Tampa, Florida, 33612, United States

  • Local Institution - 2114

    COMPLETED

    La Jolla, California, 92093, United States

  • Local Institution - 2116

    NOT_YET_RECRUITING

    New Orleans, Louisiana, 70121, United States

  • Local Institution - 2117

    COMPLETED

    New York, New York, 10016, United States

  • Local Institution - 2119

    COMPLETED

    Toledo, Ohio, 43614, United States

  • Local Institution - 2120

    COMPLETED

    Glendale, California, 91206, United States

  • Local Institution - 2121

    COMPLETED

    Long Beach, California, 90813, United States

  • Local Institution - 2122

    COMPLETED

    New Brunswick, New Jersey, 08901, United States

  • Local Institution - 2127

    COMPLETED

    Houston, Texas, 77030, United States

  • Local Institution - 2129

    COMPLETED

    Duarte, California, 91010, United States

  • Local Institution - 2131

    COMPLETED

    Boston, Massachusetts, 02215, United States

  • Local Institution - 2132

    COMPLETED

    Saint Paul, Minnesota, 55101, United States

  • Local Institution - 2133

    COMPLETED

    Baltimore, Maryland, 21210, United States

  • Local Institution - 2134

    COMPLETED

    Columbus, Georgia, 31904, United States

  • Local Institution - 2136

    WITHDRAWN

    La Jolla, California, 92037, United States

  • Local Institution - 2137

    COMPLETED

    Fairfax, Virginia, 22031, United States

  • Local Institution - 2140

    COMPLETED

    Detroit, Michigan, 48202-2608, United States

  • Local Institution - 2141

    WITHDRAWN

    Tacoma, Washington, 98405, United States

  • Local Institution - 2142

    COMPLETED

    Peoria, Illinois, 61615, United States

  • Local Institution - 2143

    COMPLETED

    Cincinnati, Ohio, 45220, United States

  • Local Institution - 2144

    COMPLETED

    Goldsboro, North Carolina, 27534, United States

  • Local Institution - 2145

    COMPLETED

    Appleton, Wisconsin, 54911, United States

  • Local Institution - 2146

    COMPLETED

    Kingwood, Texas, 77339, United States

  • Local Institution - 2147

    COMPLETED

    Bolivar, Missouri, 65613, United States

  • Local Institution - 2201

    COMPLETED

    Toronto, Ontario, M5G 2M9, Canada

  • Local Institution - 2202

    COMPLETED

    Edmonton, Alberta, T6G 1Z2, Canada

  • Local Institution - 2203

    COMPLETED

    Ontario, L6R 37R, Canada

  • Local Institution - 2204

    COMPLETED

    Ottawa, K1H 8L6, Canada

  • Local Institution - 2205

    WITHDRAWN

    Vancouver, British Columbia, V5Z 4E7, Canada

  • Local Institution - 3001

    COMPLETED

    Seoul, 03080, South Korea

  • Local Institution - 3002

    COMPLETED

    Seoul, Seodaemun-gu, 03722, South Korea

  • Local Institution - 3002

    WITHDRAWN

    Seoul, Seoul Teugbyeolsi, 03080, South Korea

  • Local Institution - 3003

    COMPLETED

    Seoul, Gangnam-gu, 06351, South Korea

  • Local Institution - 3301

    COMPLETED

    East Melbourne, 3002, Australia

  • Local Institution - 4102

    COMPLETED

    Barcelona, 08028, Spain

  • Local Institution - 4103

    COMPLETED

    Madrid, 28041, Spain

  • Local Institution - 4106

    COMPLETED

    Madrid, 28033, Spain

  • Local Institution - 4107

    COMPLETED

    Valencia, 46009, Spain

  • Local Institution - 4108

    COMPLETED

    Pamplona, 31008, Spain

  • Local Institution - 4201

    COMPLETED

    Marseille, Bouches-du-Rhône, 13005, France

  • Local Institution - 4203

    COMPLETED

    Saint-Mandé, 94163, France

  • Local Institution - 4207

    COMPLETED

    Brest, 29200, France

  • Local Institution - 4208

    COMPLETED

    Poitiers, 86000, France

  • Local Institution - 4302

    COMPLETED

    Terni, 05100, Italy

  • Local Institution - 4304

    NOT_YET_RECRUITING

    Ravenna, 48121, Italy

  • Local Institution - 4305

    COMPLETED

    Reggio Emilia, 42123, Italy

  • Local Institution - 4306

    COMPLETED

    Milan, 20122, Italy

  • Local Institution - 4307

    WITHDRAWN

    Palermo, 90146, Italy

  • Local Institution - 4401

    COMPLETED

    London, SW3 6JJ, United Kingdom

  • Local Institution - 4402

    COMPLETED

    London, W12 OHS, United Kingdom

  • Local Institution - 4403

    COMPLETED

    Manchester, M20 4BX, United Kingdom

  • Local Institution - 4404

    COMPLETED

    London, W1G 6AD, United Kingdom

  • Local Institution - 4405

    COMPLETED

    Sutton, SM2 5PT, United Kingdom

  • Local Institution - 4501

    COMPLETED

    Groningen, 9713 GZ, Netherlands

  • Local Institution - 4502

    COMPLETED

    Amsterdam, 1066 CX, Netherlands

  • Local Institution - 4602

    COMPLETED

    Warsaw, 02-781, Poland

  • Local Institution - 4603

    COMPLETED

    Szczecin, 70-784, Poland

  • Local Institution - 4604

    COMPLETED

    Lublin, 20-609, Poland

  • Local Institution - 4605

    COMPLETED

    Poznan, 60-693, Poland

  • Local Institution - 4701

    COMPLETED

    Cologne, 50937, Germany

  • Local Institution - 4702

    COMPLETED

    Heidelberg, 69120, Germany

  • Local Institution - 4703

    COMPLETED

    Dresden, 01307, Germany

  • Local Institution - 4704

    COMPLETED

    Berlin, 13125, Germany

  • Local Institution - 4801

    COMPLETED

    Leuven, 3000, Belgium

  • Local Institution - 4802

    COMPLETED

    Antwerp, 2650, Belgium

  • Local Institution - 4901

    COMPLETED

    Copenhagen, 2100, Denmark

  • Local Institution - 5101

    COMPLETED

    Budapest, 1083, Hungary

  • Local Institution - 5103

    COMPLETED

    Budapest, 1121, Hungary

  • Local Institution - 6103

    COMPLETED

    Adelaide, South Australia, 5042, Australia

  • Local Institution - 6201

    ACTIVE_NOT_RECRUITING

    Taiepi, 100, Taiwan

  • Local Institution - 6202

    COMPLETED

    Taipei, 10449, Taiwan

  • Local Institution - 6203

    ACTIVE_NOT_RECRUITING

    Tainan, 704, Taiwan

  • Local Institution - 6304

    COMPLETED

    Seoul, 06591, South Korea

  • Local Institution - 6306

    COMPLETED

    Cheongju-si, 28644, South Korea

  • Local Institution - 6307

    COMPLETED

    Seoul, 05030, South Korea

  • Local Institution - 6501

    ACTIVE_NOT_RECRUITING

    Hong Kong, Hong Kong

  • Local Institution - 6502

    ACTIVE_NOT_RECRUITING

    Hong Kong, 0, Hong Kong

  • Local Institution - 6503

    ACTIVE_NOT_RECRUITING

    Toronto, Ontario, M5G 2M9, Canada

  • Local Institution - 6504

    ACTIVE_NOT_RECRUITING

    Shatin, HONG KONG, 999077, China

  • Local Institution - 6505

    ACTIVE_NOT_RECRUITING

    Shenzhen, Guangdong, 518053, China

  • Local Institution - 6702

    COMPLETED

    Beijing, Beijing Municipality, 100021, China

  • Local Institution - 6705

    COMPLETED

    Changsha, Hunan, 410011, China

  • Local Institution - 6710

    COMPLETED

    Wuhan, Hubei, 430022, China

  • Local Institution - 6719

    COMPLETED

    Fuzhou, Fujian, 000000, China

  • Local Institution - 6725

    COMPLETED

    Hangzhou, Zhejiang, 310016, China

  • Local Institution - 6733

    COMPLETED

    Guangzhou, Guangdong, 510120, China

  • Local Institution - 6748

    COMPLETED

    Nanjing, Jiangsu, 210008, China

  • MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

  • Massachusetts General Hospital,

    RECRUITING

    Boston, Massachusetts, 02114, United States

  • Memorial Healthcare System

    RECRUITING

    Hollywood, Florida, 33021, United States

  • Nagoya University Hospital

    RECRUITING

    Nagoya, 466-8560, Japan

  • National Cancer Center Hospital East

    RECRUITING

    Kashiwa, 277-8577, Japan

  • National Cancer Center Hospital.

    RECRUITING

    Chuo-ku, Tokyo, 1040045, Japan

  • National Cancer Center Singapore

    RECRUITING

    Singapore, 169610, Singapore

  • National University Hospital

    RECRUITING

    Singapore, 119074, Singapore

  • Osaka City General Hospital

    RECRUITING

    Osaka, Osaka, 5340021, Japan

  • Osaka International Cancer institute

    RECRUITING

    Osaka, 5418567, Japan

  • Ośrodek Badań Klinicznych Wczesnych Faz, Uniwersyteckie Centrum Kliniczne

    RECRUITING

    Gdansk, 80-214, Poland

  • Peter MacCallum Cancer Centre

    RECRUITING

    Melbourne, Victoria, 3000, Australia

  • START Madrid-FJD

    RECRUITING

    Madrid, 28040, Spain

  • Samsung Medical Center

    RECRUITING

    Seoul, Seoul-teukbyeolsi [Seoul], 06351, South Korea

  • Seoul National University Hospital

    RECRUITING

    Seoul, Seoul-teukbyeolsi [Seoul], 03080, South Korea

  • Shanghai Chest Hospital

    RECRUITING

    Shanghai, 200030, China

  • Shanghai Chest Hospital

    RECRUITING

    Shanghai, 200030, China

  • Shanxi Bethune Hospital

    RECRUITING

    Taiyuan, Shanxi, 030032, China

  • Sichuan Cancer Hospital/Medical Oncology Department

    RECRUITING

    Chengdu, Sichuan, 00000, China

  • St Joseph Heritage Healthcare

    RECRUITING

    Santa Rosa, California, 95403, United States

  • Tangdu Hospital

    RECRUITING

    Xi'an, Shan3xi, 710038, China

  • The Affiliated Tumor Hospital of Harbin Medical University

    RECRUITING

    Harbin, Heilongjiang, 150081, China

  • The First Affiliated Hospital - Zhejiang University School of Medicine

    RECRUITING

    Hangzhou, 310003, China

  • The First Affiliated hospital of Xiamen University-oncology

    RECRUITING

    Xiamen, Fujian, 361003, China

  • The First Hospital Affiliated To AMU - Southwest Hospital

    RECRUITING

    Chongqing, Sichuan, 400030, China

  • The Ohio State University Wexner Medical Center

    RECRUITING

    Columbus, Ohio, 43210, United States

  • The Third Xiangya Hospital of Central South University/Department of Respiratory and Critical Care Medicine

    RECRUITING

    Changsha, 00000, China

  • The first hospital of Jilin university-Oncology Department

    RECRUITING

    Changchun, Jilin, 130021, China

  • Tottori University Hospital

    RECRUITING

    Yonago, Tottori, 683-8504, Japan

  • UT Southwestern Medical Center

    RECRUITING

    Dallas, Texas, 75390, United States

  • University Cancer and Blood Center

    RECRUITING

    Athens, Georgia, 30607, United States

  • University of Chicago

    RECRUITING

    Chicago, Illinois, 60637, United States

  • Washington University Infusion Center Pharmacy

    RECRUITING

    St Louis, Missouri, 63110, United States

  • Weifang People's Hospital/Medical Oncology Department

    RECRUITING

    Weifang, 00000, China

  • West China Hospital Sichuan University/Lung cancer center

    RECRUITING

    Chengdu, 00000, China

  • XuZhou Central Hospital/Oncology Department

    RECRUITING

    Xuzhou, Jiangsu, 00000, China

  • Yonsei University Health System, Severance Hospital

    RECRUITING

    Seoul, 03722, South Korea

  • Zhejiang Cancer Hospital-Oncology

    RECRUITING

    Hangzhou, Zhejiang, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.